

**CONSTRUCTION AND EXPRESSION OF HUMAN  
*ADIPONECTIN* IN PROKARYOTIC AND EUKARYOTIC  
EXPRESSION SYSTEMS AND THE STUDY OF ITS  
EFFECT ON SELECTED BLOOD PARAMETERS AND  
EXPRESSION OF RELATED GENES**

**HUSSIN ALWAN ROTHAN AL-MAAMURI**

**FACULTY OF SCIENCE  
UNIVERSITY OF MALAYA  
KUALA LUMPUR**

**2011**

**CONSTRUCTION AND EXPRESSION OF HUMAN  
*ADIPONECTIN* IN PROKARYOTIC AND EUKARYOTIC  
EXPRESSION SYSTEMS AND THE STUDY OF ITS EFFECT  
ON SELECTED BLOOD PARAMETERS AND EXPRESSION  
OF RELATED GENES**

**HUSSIN ALWAN ROTHAN AL-MAAMURI**

**THESIS SUBMITTED IN FULFILMENT OF  
THE REQUIREMENT FOR THE DEGREE  
OF DOCTOR OF PHILOSOPHY**

**INSTITUTE OF BIOLOGICAL SCIENCES  
FACULTY OF SCIENCE  
UNIVERSITY OF MALAYA  
KUALA LUMPUR**

**2011**

## Abstract

Adiponectin is one of the most bioactive substances secreted by adipose tissue which is involved in protection against metabolic syndrome, arteriosclerosis and type II diabetes. Research into the use of adiponectin as a promising drug for metabolic syndromes requires production of this hormone in high quantities. This may be achieved using recombinant DNA technology, which would also allow the production of different molecular forms as well as providing greater input in terms of understanding its signalling pathway. This study was mainly targeted towards producing adiponectin hormone as a recombinant protein by *P. pastoris* (P-ADP) as a cheap and convenient eukaryotic expression system for potential application in pharmaceutical therapy. For comparison, adiponectin was also expressed using the *E. coli* (E-ADP) as a traditional prokaryotic expression system. Following successful expression, the relative bio-properties of P-ADP was assessed *in vivo* in comparison with E-ADP. Additional studies of the effect of P-ADP on the expression of the genes encoding glucagon, insulin and leptin receptors were carried out.

*Adiponectin* gene was constructed *in vitro* by splicing its two exons using overlap-extension PCR. Full length *adiponectin* was amplified by PCR and cloned into pMAL™-p4 vector for expression in *E. coli* as periplasmic secreted protein. The fusion protein was purified by amylose column after digestion with factor Xa. To express *adiponectin* in *P. pastoris*, the full length *adiponectin* was amplified by cloning into pGEM-T vector and then sub-cloning into pPICZαA vector to be expressed as extracellular secreted protein. The 6xHis-tagged recombinant adiponectin was purified by one step affinity chromatography using Nickel column. SDS-PAGE and western blot were used to detect and analyse the recombinant proteins and Bradford assay was used for protein quantification. Three experiments were designed to assess and compare the effects of E-ADP and P-ADP on blood glucose and lipid profile using ICR mice as a

model system. Real-Time PCR was used to examine the changes in the regulation of glucagon, insulin and leptin receptors after administration with P-ADP. The expression of target genes was normalized with  $\beta$ -actin as endogenous gene and the data was statistically analysed based on  $\Delta ct$  values and RQ values using t-test. The results showed that *adiponectin* gene was successfully constructed *in vitro* by overlap-extension PCR and expressed by *E. coli* as a soluble periplasm protein and by *P. pastoris* as a soluble extracellular protein. *P. pastoris* expression system was successful in producing high molecular weight of adiponectin molecules and relatively high quantity of recombinant protein (0.1 mg/ml) as compared with *E.coli* (0.04 mg/ml). The optimum conditions of adiponectin production by *P. pastoris* were 0.5% of methanol induction every 12 hours for 60 hours at 30°C. E-ADP and P-ADP were biologically active in the lowering of blood glucose and triglyceride and increasing high density lipoprotein. The ability of P-ADP in lowering blood glucose was significantly higher than E-ADP. However, there was no significant difference on the effect on lipid profile. P-ADP significantly down-regulates glucagon receptors and up-regulates leptin receptors, whilst there was no significant effect on insulin receptors. Our results suggest that *P. pastoris* expression system is better in producing high quantity, high biological activity and easily purified recombinant adiponectin comparing with *E. coli* expression system that can be used in large scale production of adiponectin as potential drugs for metabolic syndromes.

## ACKNOWLEDGEMENTS

This project was supported through UMRG Research University grant RG022/09B10 and short term grant PS232/2008C, awarded to the author and his supervisor by the University Malaya and Ministry of Higher Education, Malaysia. The author wishes to thank these funding bodies for enabling this project to be completed. The author also wishes to acknowledge Faculty of Science, University of Malaya for access and use of all relevant facilities and many thanks to Center for Biotechnology Research in Agriculture (CEBAR) for use of equipments and facilities. The main person who guided me through all the steps in this work was my supervisor Associate Professor Dr. Zulqarnain Bin Mohamed, who gave ideas, time, support, and encouraged me to do the best; he deserves the highest respect and thanks. Many thanks and appreciation to Miss Teh Ser Huy. She provided so much gracious help with the research. Much appreciation is also expressed to Associate Professor Dr. Mahmood Ameen Abdulla who provided help, and research associates for bioassay experiments. I would really like to thank all my wonderful lab mates. Personally, I would like to thank my wife Rehab for her patience and support, and also to my brothers and sisters.

<b>Contents</b>	<b>Page</b>
<b>Abstract</b>	<b>i</b>
<b>Acknowledgements</b>	<b>iii</b>
<b>contents</b>	<b>iv</b>
<b>List of figures</b>	<b>xi</b>
<b>List of tables</b>	<b>xvi</b>
<b>Abbreviations</b>	<b>xvii</b>

***Chapter 1: Introduction***

1.1.	Adiponectin	1
1.1.1.	<i>Adiponectin</i> gene characteristics	6
1.1.2.	Adiponectin protein characteristics	7
1.1.3.	Glycosylation of adiponectin protein	11
1.1.4.	Regulation of <i>adiponectin</i> gene expression	13
1.1.5.	<i>Adiponectin</i> single nucleotide polymorphisms (SNPs)	17
1.1.6.	Adiponectin biological activity	20
1.1.6.1.	Anti-diabetic properties of adiponectin	22
1.1.6.2.	Anti-atherogenic, anti-inflammatory and cardioprotective properties of adiponectin	27
1.2.	Expression of proteins in prokaryotic and eukaryotic expression systems.	30
1.2.1.	Expression in <i>Escherichia coli</i>	31
1.2.1.1.	The features of <i>E. coli</i> expression system	32
1.2.1.2.	Formation of inclusion bodies and protein folding	34

## Contents

1.2.2.	<i>Pichia pastoris</i> expression system	38
1.2.2.1.	Advantages of using <i>P. pastoris</i> as an expression system	39
1.2.2.2.	<i>Pichia pastoris</i> promoters	41
1.3.	Objectives of study	42

## Chapter 2: Materials and Methods

2.1.	Construction of human <i>adiponectin</i> by overlap-extension PCR	44
2.1.1.	Primers design	44
2.1.1.1.	Primer design for expression of <i>adiponectin</i> in <i>P. pastoris</i>	44
2.1.1.2.	Primer design for expression of <i>adiponectin</i> in <i>E. coli</i>	45
2.1.2.	PCR reaction	47
2.2.	Agarose gel electrophoresis	48
2.3.	DNA extraction by gel extraction kit	48
2.4.	<i>Adiponectin</i> expression by <i>E. coli</i>	49
2.4.1.	Preparation of Luria-Bertani (LB) broth and agar media	49
2.4.2.	Competent cells preparation of TB1 <i>E. coli</i> strain	50
2.4.3.	Cloning of <i>adiponectin</i> into pMAL <sup>TM</sup> vector	50
2.4.4.	Transformation into <i>E. coli</i>	53
2.4.5.	Colony screening PCR	53
2.4.6.	Small scale expression of <i>adiponectin</i> by <i>E. coli</i>	54
2.4.7.	Native sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDS-PAGE) and SDS-PAGE without	54

## Contents

	denaturing condition.	
2.4.8.	Western blot	56
2.4.9.	Scale up expression of adiponectin by <i>E. coli</i>	57
2.4.10.	Protein purification by amylose resin column	58
2.4.11.	Cleavage, denaturing and re-purification of recombinant protein	58
2.4.12.	Bradford assay	59
2.5.	Adiponectin expression by <i>Pichia pastoris</i>	59
2.5.1.	Cloning of <i>adiponectin</i> into pGEM-T vector	60
2.5.1.1.	Ligation reaction	60
2.5.1.2.	Transformation	60
2.5.1.3.	Colony selection	61
2.5.1.4.	Plasmid isolation	61
2.5.1.5.	Restriction enzyme digestion of pGEMT- <i>adiponectin</i> recombinant plasmid	63
2.5.2.	Clone of <i>adiponectin</i> in pPICZαA vector	63
2.5.2.1.	Preparation of Low Salt Luria-Bertani (LSLB) broth and agar media	64
2.5.2.2.	Preparation of Top10F <i>E. coli</i> competent cells	64
2.5.2.3.	Ligation reaction	64
2.5.2.4.	Transformation	65
2.5.2.5.	Colony selection	65
2.5.2.6.	Plasmid isolation	65
2.5.2.7.	Linearization of the recombinant plasmid	66
2.5.3.	Cloning into <i>Pichia pastoris</i>	66

## Contents

2.5.3.1.	Preparation of <i>P. pastoris</i> broth and agar media	66
2.5.3.2.	Preparation of <i>P. pastoris</i> competent cells	67
2.5.3.3.	Transformation	67
2.5.3.4.	Selection of positive colonies	68
2.5.3.4.1.	Colony selection via PCR	68
2.5.3.4.2.	Colonies capacity of the Zeocin™ resistance	69
2.5.3.4.3.	Differentiation between Mut <sup>+</sup> and Mut <sup>S</sup> phenotypes	69
2.5.3.5.	Preparation of expression media	69
2.5.3.6.	Protein expression and optimization	70
2.5.3.7.	Protein purification	71
2.5.3.8.	Scale-up expression of recombinant adiponectin	71
2.5.4.	Bioactivity tests	72
2.5.4.1.	Effect of recombinant adiponectin produced by <i>P. pastoris</i> and <i>E. coli</i> on blood glucose and lipids.	73
2.5.4.2.	High and low doses effect of recombinant adiponectin on blood glucose and lipid profile.	73
2.5.4.3.	Oral glucose tolerance test	74
2.5.5.	Assessment of genes expression	74
2.5.5.1.	Total RNA extraction	74
2.5.5.2.	DNase treatment	75

## Contents

2.5.5.3.	cDNA preparation	76
2.5.5.4.	Real-Time PCR	78
2.5.4.4.1.	Primers design and validation	81
2.5.4.4.2.	Data analysis of Real-Time PCR	84
<b>Chapter 3: Results</b>		
3.1.	<i>In vitro</i> construction of <i>adiponectin</i>	86
3.2.	Expression of <i>adiponectin</i> gene in <i>E. coli</i>	91
3.2.1.	Restriction enzyme digestion	93
3.2.2.	Selection of recombinant <i>E. coli</i> colonies	95
3.2.3.	Sequencing analysis	98
3.2.4.	Recombinant adiponectin analysis	100
3.2.5.	Scale up expression of <i>adiponectin</i> by <i>E. coli</i>	103
3.2.6.	Recombinant adiponectin purification	103
3.3.	Expression of <i>adiponectin</i> by <i>Pichia pastoris</i>	108
3.3.1.	Cloning of <i>adiponectin</i> in pGEM-T vector	110
3.3.2.	<i>EcoRI</i> and <i>NotI</i> digestion	114
3.3.3.	Cloning of <i>adiponectin</i> in pPICZ $\alpha$ A	118
3.3.4.	Sequencing data	121
3.3.5.	Transformation into <i>Pichia pastoris</i>	124
3.3.6.	Colony selection	126
3.3.7.	Selection of Mut <sup>+</sup> phenotype with high insertion copy number colonies	129
3.3.8.	Small scale expression of adiponectin	131
3.3.9.	Optimization of adiponectin expression	134

## Contents

3.3.10.	Analysis of recombinant adiponectin protein produced by <i>E. coli</i> and <i>P. pastoris</i>	140
3.4.	Biological activity assessment of recombinant adiponectin	142
3.4.1.	Comparison of adiponectin bioactivity produced by <i>P. pastoris</i> and <i>E. coli</i>	142
3.4.2.	Effect of the high and low doses of P-ADP on blood glucose and lipid profile	145
3.4.3.	Oral glucose tolerant test	148
3.5.	Effect of P-ADP administration on the expression of glucagon, insulin and leptin receptors	150
3.5.1.	Total RNA extraction and DNase treatment	150
3.5.2.	RT- PCR	152
3.5.2.1.	Expression of glucagon receptors	152
3.5.2.2.	Expression of insulin receptors	157
3.5.2.3.	Expression of leptin receptors	162

## Chapter 4: Discussion

4.1.	<i>In vitro</i> gene construction	168
4.2.	Expressions of adiponectin in prokaryotic and eukaryotic expression systems	172
4.2.1.	Expression of adiponectin by <i>E. coli</i>	173
4.2.1.1.	Adiponectin protein solubility	175
4.2.1.2.	Adiponectin protein purification	177
4.2.2.	Adiponectin expression by <i>Pichia pastoris</i>	178
4.2.2.1.	Production of adiponectin as extracellular	179

## Contents

	secreted protein	
	4.2.2.2. Optimization of protein expression	180
	4.2.2.3. Protein solubility	182
	4.2.3. Comparison between <i>adiponectin</i> expression in <i>E. coli</i> and <i>P. pastoris</i>	182
4.3.	Adiponectin bioactivity	184
	4.3.1. Effects of E-ADP and P-ADP on blood glucose	185
	4.3.2. P-ADP potential in lowering blood glucose	187
	4.3.3. Effects of E-ADP and P-ADP on lipid profile	189
4.4.	Effect of P-ADP administration on related gene expression	191
	4.4.1. Effect of P-ADP administration on the expression of glucagon receptors	192
	4.4.2. Effect of P-ADP administration on the expression of insulin receptors	193
	4.4.3. Effect of P-ADP administration on the expression of leptin receptors	193
4.5.	Summary and conclusion	195
	<b>References</b>	198
	<b>Appendices</b>	
	Appendix A	Coference abstracts and presentations
	Appendix B	Awards received

## *Contents*

<b><i>List of figures</i></b>		<b>Page</b>
Figure 1.1	Summary of the diversity of cell-signalling responses to adipokines	2
Figure 1.2	Research interest in adiponectin, a protein secreted by adipose tissue	4
Figure 1.3	The relationships between plasma adiponectin levels, obesity and insulin resistance	5
Figure 1.4	Structure and adiponectin domains	8
Figure 1.5	Multimer formation of adiponectin	10
Figure 1.6	Structural characteristics of adiponectin protein.	12
Figure 1.7	Regulation of adiponectin synthesis and function.	14
Figure 1.8	PPAR $\gamma$ agonists thiazolidinediones (TZDs) ameliorate insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.	16
Figure 1.9	Diagram of polymorphic variants of the <i>adiponectin</i> gene.	19
Figure 1.10	Main target organs and bio-activities of adiponectin.	21
Figure 1.11	The hypothesis of adiponectin effect on metabolic syndromes.	23
Figure 1.12	Proposed structure of adiponectin receptors.	26
Figure 1.13	Signal transduction by adiponectin receptors.	26
Figure 1.14	Adiponectin functions as anti-atherogenic factor.	29
Figure 1.15	The pathway of protein folding and secretion in <i>E. coli</i>	37
Figure 2.1	The design of RT-PCR experiment.	80
Figure 2.2	Melt curves of each gene of interest and an endogenous gene.	83
Figure 3.1	<i>In vitro</i> construction of <i>ADPs</i> .	88
Figure 3.2	<i>In vitro</i> construction of <i>ADP<sub>ws</sub></i> .	89
Figure 3.3	Amplification of <i>ADPs</i> and <i>ADP<sub>ws</sub></i> using different primers for	90

	cloning into <i>P.pastoris</i> and <i>E.coli</i> .	
Figure 3.4	The map of pMAL <sup>TM</sup> -p4x and pMAL <sup>TM</sup> -c4x vectors explaining enzymes restriction sites.	92
Figure 3.5	Restriction enzyme digestion for cloning into <i>E. coli</i>	94
Figure 3.6	Agarose gel electrophoresis of colony screening ADPs.	96
Figure 3.7	Agarose gel electrophoresis of colony screening for ADP <sub>WS</sub> .	97
Figure 3.8	Sequencing data of ADPs.	99
Figure 3.9	SDS-PAGE analysis of adiponectin expression before and after induction with IPTG.	101
Figure 3.10	Western blot analysis of adiponectin expression before and after induction with IPTG.	102
Figure 3.11	Purification by amylose resin column.	104
Figure 3.12	SDS-PAGE for optimization of Factor Xa digestion.	106
Figure 3.13	SDS-PAGE for second purification by hydroxyapatite column and amylose resin column.	107
Figure 3.14	The map of pPICZα A plasmid that was used to clone the gene of interest into <i>P. pastoris</i> .	109
Figure 3.15	PGEMT-vector map.	111
Figure 3.16	Agarose gel electrophoresis of colony selection by PCR using M13 forward and reverse primers to detect existence of ADP <sub>WS</sub> .	112
Figure 3.17	Agarose gel electrophoresis of colony selection by PCR using M13 forward and reverse primers to confirm existence of ADPs.	113
Figure 3.18	Agarose gel electrophoresis of <i>adiponectin</i> -pGEMT recombinant plasmid.	115
Figure 3.19	Agarose gel electrophoresis of restriction enzyme digestion to	115

	generate <i>ADPs</i> with two sticky ends.	
Figure 3.20	Agarose gel electrophoresis of restriction enzyme digestion to generate <i>ADP<sub>ws</sub></i> with two sticky ends.	116
Figure 3.21	Agarose gel electrophoresis of pPICZ $\alpha$ A plasmid digestion with <i>EcoRI</i> and <i>NotI</i> .	117
Figure 3.22	Colony screening PCR using $\alpha$ -factor forward primer and 3'AOX1 reverse primer to detect <i>ADP<sub>ws</sub></i> .	119
Figure 3.23	Colony screening PCR using $\alpha$ -factor forward primer and 3'AOX1 reverse primer to detect <i>ADPs</i> .	120
Figure 3.24	Sequencing data of <i>ADP<sub>ws</sub></i> after cloning in pPICZ $\alpha$ A.	122
Figure 3.25	The sequence of <i>ADPs</i> after cloning in pPICZ $\alpha$ A.	123
Figure 3.26	Recombinant plasmid linearization with <i>SacI</i> restriction enzyme.	125
Figure 3.27	Colony PCR screening using $\alpha$ -factor forward primer and 3'AOX1 reverse primer to detect <i>ADP<sub>ws</sub></i> into yeast colonies.	127
Figure 3.28	Colony screening PCR using $\alpha$ -factor forward primer and 3'AOX1 reverse primer to detect <i>ADPs</i> into yeast colonies.	128
Figure 3.29	Multi insertion of expression cassette into yeast cells.	130
Figure 3.30	SDS- PAGE analysis of the supernatant collected from cultures inoculated with yeast colonies carrying <i>ADP<sub>ws</sub></i> .	132
Figure 3.31	SDS- PAGE analysis of the supernatant collected from cultures inoculated with yeast colonies carrying <i>ADPs</i> .	133
Figure 3.32	The growth rate of yeast during time course expression.	135
Figure 3.33	SDS-PAGE analysis of the time course for adding methanol and culture harvesting every 12 hours after methanol induction.	136
Figure 3.34	Western blot analysis of the time course for adding methanol and culture harvesting every 12 hours after induction.	137

Figure 3.35	SDS-PAGE without denaturing condition showed less oligomers for E-ADP compared with P-ADP.	141
Figure 3.36	Effect of P-ADP and E-ADP on the levels of blood glucose.	143
Figure 3.37	Effect of P-ADP and E-ADP on lipid profile.	144
Figure 3.38	Effect of the high and low doses of P-ADP on blood glucose levels.	146
Figure 3.39	Effect of the high and low doses of P-ADP on blood lipid profile.	147
Figure 3.40	Oral glucose tolerance test.	149
Figure 3.41	Total RNA extraction by TRIzol™ method.	151
Figure 3.42	Total RNA after DNase treatment.	151
Figure 3.43	Expression of glucagon receptors: The comparative $\Delta Ct$ value of the biological groups that contain control or treatment groups.	153
Figure 3.44	Expression of glucagon receptors: The mean of biological group's $\Delta Ct$ value for liver, abdominal fat tissue and kidney for treatment and control groups.	154
Figure 3.45	Expression of glucagon receptors: Relative quantification differences between treatment and control groups.	156
Figure 3.46	Expression of insulin receptors: The comparative $\Delta Ct$ value of the biological groups that contain control or treatment groups.	158
Figure 3.47	Expression of insulin receptors: The mean of biological group's $\Delta Ct$ value for liver, abdominal fat tissue, skeletal muscle and kidney for treatment and control groups.	159
Figure 3.48	Expression of insulin receptors: Relative quantification differences between treatment and control groups.	161
Figure 3.49	Expression of leptin receptors: The comparative $\Delta Ct$ value of the	163

	biological groups that contain control or treatment groups.	
Figure 3.50	Expression of leptin receptors: The mean of biological group's $\Delta Ct$ value for liver, abdominal fat tissue and kidney for treatment and control groups.	164
Figure 3.51	Expression of leptin receptors: Relative quantification differences between treatment and control groups.	166
Figure 4.1	<i>In vitro</i> construction of <i>adiponectin</i> gene by overlap-extension PCR	170

<b><i>List of tables</i></b>		Page
Table 2.1	Sequences of primers used to express <i>adiponectin</i> in <i>P. pastoris</i> .	46
Table 2.2	Sequences of primers used to express <i>adiponectin</i> in <i>E. coli</i> .	46
Table 2.3	The components of the ligation mix.	52
Table 2.4	The components of 2X RT master mix.	77
Table 2.5	Thermal cycle conditions of RT reaction.	77
Table 2.6	The components of RT-PCR reaction	79
Table 2.7	Thermal cycle conditions of RT-PCR reaction	79
Table 2.8	Forward and reverse primers for each gene of interest and an endogenous gene.	82
Table 3.1	The differences were observed in the optical density, total cells mass and protein concentration at different time points after methanol induction.	139
Table 3.2	The results of real time PCR and the results of statistical analysis for mean $\Delta Ct$ values and relative quantification values ( $RQ$ ) using <i>t-test</i> statistical analysis.	155
Table 3.3	The results of real time PCR and the results of statistical analysis for mean $\Delta Ct$ values and relative quantification values ( $RQ$ ) using <i>t-test</i> statistical analysis.	160
Table 3.4	The results of real time PCR and the results of statistical analysis for mean $\Delta Ct$ values and relative quantification values ( $RQ$ ) using <i>t-test</i> statistical analysis.	165

## ***Abbreviations***

3T3-L1	Cell line derived from 3T3 cells used in biological research on adipose tissue.
°C	degree Celsius
µg	microgram
µg/ml	microgram per millilitre
µl	microlitre
µM	micro Molar
3T3-F442A	preadipocyte cell lines
<i>ADPs</i>	adiponectin DNA fragment with signal peptide sequence
<i>ADP<sub>WS</sub></i>	adiponectin DNA fragment without signal peptide sequence
AMPK	5' adenosine monophosphate-activated protein kinase
AOX	Alcohol oxidase
APS	ammonium persulfate
TEMED	N, N, N', N'-tetramethylethylenediamine
Arg	Arginine
BMGY	Buffered Glycerol-complex Medium
BMMY	Buffered Methanol-complex Medium
bp	base pair
BSA	bovine serum albumin
BW	Body weight
CaCl <sub>2</sub>	calcium chloride
cDNA	complementary DNA

*Abbreviation*

CDS	coding sequence
CHO	Chinese hamster ovary
CHOL	total cholesterol
<i>Ct</i>	Cycle time
CV	coefficient of variation
Cys	cysteine
DEPC	Diethylpyrocarbonate
DNA	deoxyribonucleic acid
dNTPs	Deoxyribonucleoside triphosphate
e.g	for example
E-ADP	recombinant adiponectin expressed in <i>E. coli</i>
EDTA	ethylenediaminetetraacetic acid
ERp44	endoplasmic reticulum folding assistant protein
<i>et al.</i>	<i>et alii</i> (and other people)
EtBr	ethidium bromide
<i>FLD1</i>	formaldehyde dehydrogenase gene
g/L	gram per litre
Glu	Glutamic acid
Gly	Glycine
HDL	high density lipoprotein
His	Histidine
HMW	High molecular weight
hrs	hours
i.e.	that is
IGF-1	Insulin like growth factor 1
Ile	Isoleucine

*Abbreviation*

IPTG	isopropyl-beta-dthiogalactopyranoside
kb	kilo bases
kDa	kilo dalton
KOAc	potassium acetate
lbs/sq.in.	pounds per square inch
LB	Luria-Bertani broth
LDL	low-density lipoproteins
LMW	Low molecular weight
LSLB	low salt Luria-Bertani broth
M	molar
MBP	maltose binding protein
mg/L	milligram per litre
mg/ml	milligram per millilitre
Mg <sup>2+</sup>	magnesium ion
min	minute
mM	milli Molar
mRNA	messenger RNA
Mut <sup>-</sup>	methanol utilization minus
Mut <sup>+</sup>	methanol utilization plus
Mut <sup>S</sup>	methanol utilization slow
NaCl	sodium chloride
NaOH	sodium hydroxide
ng	nanogram
Ni	nickel
nm	nanometer
O <sub>2</sub>	oxygen

*Abbreviation*

OD <sub>600</sub>	optical density at 600nm
P-ADP	recombinant adiponectin expressed in <i>P. pastoris</i>
PAGE	polyacrylamide gel electrophoresis
<i>PAOX1</i>	promoter from the alcohol oxidase 1 gene
PBS	phosphate buffered saline
PCR	polymerase chain reaction
<i>Pfu</i>	<i>Pyrococcus furiosus</i>
PPAR $\gamma$	peroxisome proliferator-activated receptor $\gamma$
Pro	proline
RNA	ribonucleic acid
RNase A	ribonuclease A
rpm	revolutions per minute
<i>RQ</i>	relative quantification
RT	reverse transcription
RT-PCR	Real-Time PCR
s	second
sdH <sub>2</sub> O	sterile distilled water
SDS	sodium dodecyl sulfate
<i>SEM</i>	standard error means
Ser	Serine
SNPs	single nucleotide polymorphisms
<i>Stdev</i>	standard deviation
<i>Taq</i>	<i>Thermus aquaticus</i>
TBE	Tris Borate EDTA
TBS	Tris buffered saline
TBST	Tris buffered saline-Tween 20

*Abbreviation*

TCA	trichloroacetic acid
TE	Tris-EDTA
TG	triglyceride
T <sub>m</sub>	Melting temperature
TNF- $\alpha$	Tumor necrosis factor-alpha
TZDs	thiazolidinediones
U	unit
UV	ultraviolet
V	volume
X-Gal	bromo-chloro-indolyl-galactopyranoside
YPD	Yeast Extract Peptone Dextrose